Perrot A, et al. - In multiple myeloma, the predictive value of minimal residual disease (MRD), measured during maintenance therapy by next-generation sequencing, was determined by analyzing data from a recent clinical trial that assessed the role of transplantation in newly diagnosed myeloma patients treated with lenalidomide, bortezomib, and dexamethasone (RVD). The accepted definition of MRD negativity was the absence of tumor plasma cell within 1,000,000 bone marrow cells (<10^-6). MRD was identified as a strong prognostic factor for both progression-free survival and overall survival at the start of maintenance therapy. MRD status, as determined by next-generation sequencing, was confirmed to have value as a prognostic biomarker in multiple myeloma.